Cardiac troponin T and advanced glycation end-products in hemodialysis patients.
Cardiac troponin T (cTnT) is used as a biomarker of myocardial damage for the diagnosis of acute myocardial infarction and acute coronary syndrome. The aim was to investigate the association between advanced glycation end products (AGEs) and cTnT in hemodialysis (HD) patients. The plasma level of cTnT in 224 HD patients was measured using the electrochemiluminescence immunoassay. The plasma levels of N(epsilon)-(carboxymethyl)lysine (CML) and pentosidine were measured using an enzyme-linked immunosorbent assay. The cTnT-positive group (>0.1 ng/ml) showed significantly high plasma levels of calcium, CML and pentosidine as compared with the cTnT-negative group. In multiple logistic regression analysis, the prevalence of patients with high plasma calcium (>median) was increased in the cTnT-positive group as compared with the cTnT-negative group (OR: 5.08, 95% CI: 1.62-15.92, p < 0.01). The prevalence of high plasma CML (>median) was increased in the cTnT-positive group (OR: 4.45, 95% CI: 1.41-14.03, p < 0.05). Further, the prevalence of high plasma pentosidine (>median) was also increased in the cTnT-positive group (OR: 4.94, 95% CI: 1.55-15.70, p < 0.01). In addition to calcium, AGEs such as CML and pentosidine were associated with cTnT, a marker of myocardial damage, in HD patients.